MDCO Gets 2nd Shot At Angiomax Patent Extension
The Medicines Co. has prevailed in its attempt to have the U.S. Patent and Trademark Office reconsider extending a patent for blood-thinning drug Angiomax....To view the full article, register now.
Already a subscriber? Click here to view full article